Kestra Medical Technologies Reports 59% Revenue Growth to $95.1 Million, Despite Increased Net Loss

Kestra Medical Technologies, Ltd. reported significant financial developments in its recent 10-K filing, highlighting a 59% increase in revenue for the fiscal year ending April 30, 2026, amounting to $95.1 million, compared to $59.8 million in the previous year. This growth was primarily driven by a 58% rise in the number of patients utilizing its ASSURE Wearable Cardioverter Defibrillator (WCD). Despite this revenue increase, the company recorded a net loss of $131.6 million, up from a loss of $113.8 million in the prior fiscal year, reflecting ongoing investments in research, development, and commercialization efforts.

The company's cost of revenue also rose, increasing by 30% to $46.3 million, largely due to higher expenses associated with disposable medical equipment and equipment reconditioning, which were directly linked to the increased patient count. Gross profit doubled to $48.9 million, attributed to improved operational efficiencies and a decrease in costs per patient. However, total operating expenses surged by 41% to $183.6 million, driven by increased personnel costs and expenses related to the transition to a public company.

Strategically, Kestra has expanded its commercial operations, increasing its sales force from 80 to approximately 130 representatives over the year. The company also plans to pursue international market opportunities, particularly in Western Europe, where it aims to obtain CE Mark approval for its products. As of April 30, 2026, Kestra had cash, cash equivalents, and investments totaling $262.2 million, bolstered by net proceeds from its initial public offering (IPO) and subsequent secondary offering, which collectively raised over $336 million.

Looking ahead, Kestra's management expressed confidence in its ability to fund operations for at least the next 12 months, although it acknowledged the potential need for additional financing to support growth initiatives. The company remains focused on enhancing its Cardiac Recovery System platform and expanding its market presence, while also navigating the complexities of regulatory compliance and reimbursement challenges in the healthcare sector.